[Clinical Management of Lung Cancer Patients during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19)].
Identifieur interne : 000533 ( PubMed/Corpus ); précédent : 000532; suivant : 000534[Clinical Management of Lung Cancer Patients during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19)].
Auteurs : Yan Xu ; Hongsheng Liu ; Ke Hu ; Mengzhao WangSource :
- Zhongguo fei ai za zhi = Chinese journal of lung cancer [ 1999-6187 ] ; 2020.
English descriptors
- KwdEn :
- MESH :
- geographic : China.
- diagnosis : Lung Neoplasms.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- pathogenicity : Betacoronavirus.
- therapy : Lung Neoplasms.
- Disease Outbreaks, Disease Susceptibility, Humans, Immunocompromised Host, Patient Care Planning, Risk.
Abstract
Since late December 2019, an outbreak of 2019 novel coronavirus diseases (COVID-19) in Wuhan, China has spread quickly nationwide. With the spread of COVID-19, the routine clinical diagnosis and treatment for lung cancer patients has been disturbed. Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals. Furthermore, patients with cancer had poorer prognosis from infection. Lung cancer patients should be the priority group for COVID-19 prevention. The protection provisions and control measures aiming to protect lung cancer patients from COVID-19 have been increasingly concerned. During the COVID-19 outbreak period, it should be carefully differentiated for fever and respiratory symptoms for lung cancer patients receiving anti-tumor treatment, in order to evaluate the risk of COVID-19. Moreover, it is necessary to carry out meticulous and individualized clinical management for lung cancer patients to effectively protect the patients from COVID-19.
DOI: 10.3779/j.issn.1009-3419.2020.03.02
PubMed: 32077441
Links to Exploration step
pubmed:32077441Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Clinical Management of Lung Cancer Patients during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19)].</title><author><name sortKey="Xu, Yan" sort="Xu, Yan" uniqKey="Xu Y" first="Yan" last="Xu">Yan Xu</name><affiliation><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Hongsheng" sort="Liu, Hongsheng" uniqKey="Liu H" first="Hongsheng" last="Liu">Hongsheng Liu</name><affiliation><nlm:affiliation>Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Hu, Ke" sort="Hu, Ke" uniqKey="Hu K" first="Ke" last="Hu">Ke Hu</name><affiliation><nlm:affiliation>Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Mengzhao" sort="Wang, Mengzhao" uniqKey="Wang M" first="Mengzhao" last="Wang">Mengzhao Wang</name><affiliation><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32077441</idno><idno type="pmid">32077441</idno><idno type="doi">10.3779/j.issn.1009-3419.2020.03.02</idno><idno type="wicri:Area/PubMed/Corpus">000533</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000533</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Clinical Management of Lung Cancer Patients during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19)].</title><author><name sortKey="Xu, Yan" sort="Xu, Yan" uniqKey="Xu Y" first="Yan" last="Xu">Yan Xu</name><affiliation><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Hongsheng" sort="Liu, Hongsheng" uniqKey="Liu H" first="Hongsheng" last="Liu">Hongsheng Liu</name><affiliation><nlm:affiliation>Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Hu, Ke" sort="Hu, Ke" uniqKey="Hu K" first="Ke" last="Hu">Ke Hu</name><affiliation><nlm:affiliation>Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Mengzhao" sort="Wang, Mengzhao" uniqKey="Wang M" first="Mengzhao" last="Wang">Mengzhao Wang</name><affiliation><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Zhongguo fei ai za zhi = Chinese journal of lung cancer</title><idno type="eISSN">1999-6187</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (pathogenicity)</term><term>China</term><term>Coronavirus Infections (epidemiology)</term><term>Disease Outbreaks</term><term>Disease Susceptibility</term><term>Humans</term><term>Immunocompromised Host</term><term>Lung Neoplasms (diagnosis)</term><term>Lung Neoplasms (therapy)</term><term>Patient Care Planning</term><term>Pneumonia, Viral (epidemiology)</term><term>Risk</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>China</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Outbreaks</term><term>Disease Susceptibility</term><term>Humans</term><term>Immunocompromised Host</term><term>Patient Care Planning</term><term>Risk</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Since late December 2019, an outbreak of 2019 novel coronavirus diseases (COVID-19) in Wuhan, China has spread quickly nationwide. With the spread of COVID-19, the routine clinical diagnosis and treatment for lung cancer patients has been disturbed. Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals. Furthermore, patients with cancer had poorer prognosis from infection. Lung cancer patients should be the priority group for COVID-19 prevention. The protection provisions and control measures aiming to protect lung cancer patients from COVID-19 have been increasingly concerned. During the COVID-19 outbreak period, it should be carefully differentiated for fever and respiratory symptoms for lung cancer patients receiving anti-tumor treatment, in order to evaluate the risk of COVID-19. Moreover, it is necessary to carry out meticulous and individualized clinical management for lung cancer patients to effectively protect the patients from COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32077441</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1999-6187</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><PubDate><Year>2020</Year><Month>02</Month><Day>20</Day></PubDate></JournalIssue><Title>Zhongguo fei ai za zhi = Chinese journal of lung cancer</Title><ISOAbbreviation>Zhongguo Fei Ai Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Clinical Management of Lung Cancer Patients during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19)].</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.3779/j.issn.1009-3419.2020.03.02</ELocationID><Abstract><AbstractText>Since late December 2019, an outbreak of 2019 novel coronavirus diseases (COVID-19) in Wuhan, China has spread quickly nationwide. With the spread of COVID-19, the routine clinical diagnosis and treatment for lung cancer patients has been disturbed. Due to the systemic immunosuppressive of lung cancer patients caused by the malignancy and anticancer treatments, lung cancer patients are more susceptible to infection than healthy individuals. Furthermore, patients with cancer had poorer prognosis from infection. Lung cancer patients should be the priority group for COVID-19 prevention. The protection provisions and control measures aiming to protect lung cancer patients from COVID-19 have been increasingly concerned. During the COVID-19 outbreak period, it should be carefully differentiated for fever and respiratory symptoms for lung cancer patients receiving anti-tumor treatment, in order to evaluate the risk of COVID-19. Moreover, it is necessary to carry out meticulous and individualized clinical management for lung cancer patients to effectively protect the patients from COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hongsheng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Mengzhao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhongguo Fei Ai Za Zhi</MedlineTA><NlmUniqueID>101126433</NlmUniqueID><ISSNLinking>1009-3419</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657245">COVID-19</NameOfSubstance></Chemical><Chemical><RegistryNumber>txid2697049</RegistryNumber><NameOfSubstance UI="C000656484">severe acute respiratory syndrome coronavirus 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="Y">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="Y">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010347" MajorTopicYN="N">Patient Care Planning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText>【中文题目：新型冠状病毒肺炎疫情期间肺癌患者临床管理】 【中文摘要：自2019年12月底以来，湖北省武汉市陆续发现多例新型冠状病毒肺炎（简称：新冠肺炎，2019 novel coronavirus disease，COVID-19），并在全国范围内蔓延。随着新冠肺炎疫情的蔓延，肺癌患者的常规医疗受到影响。由于肺癌患者接受抗肿瘤治疗后免疫力低，合并感染后症状重，应是疫情防治的重点对象，肺癌患者对新冠肺炎的防范措施日益受到关注。复杂严峻的新冠肺炎疫情下，接受抗肿瘤治疗的肺癌患者如出现发热及呼吸道症状，更需要仔细地进行鉴别诊断，评估新冠肺炎感染的风险。对于肺癌患者，在新冠肺炎疫情期间，需要进行精细化和个体化的管理，最大程度地保护患者，有效防范新冠肺炎。】 【中文关键词：肺肿瘤；患者管理； 新型冠状病毒肺炎】.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">2019 novel coronavirus disease</Keyword><Keyword MajorTopicYN="Y">Lung neoplasms</Keyword><Keyword MajorTopicYN="Y">Patient management</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32077441</ArticleId><ArticleId IdType="doi">10.3779/j.issn.1009-3419.2020.03.02</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000533 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000533 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:32077441
|texte= [Clinical Management of Lung Cancer Patients during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19)].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:32077441" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidV1
| This area was generated with Dilib version V0.6.33. |  |